Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.48 USD | +0.59% | -2.75% | -18.38% |
May. 02 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 68% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.38% | 604M | - | ||
+11.91% | 118B | B+ | ||
+11.60% | 106B | B+ | ||
-4.68% | 24.28B | B+ | ||
-0.82% | 21.96B | B | ||
-10.12% | 18.16B | A- | ||
-42.12% | 16.37B | A- | ||
-17.47% | 15.56B | B | ||
+2.77% | 13.63B | C+ | ||
+34.58% | 12.27B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZYME Stock
- Ratings Zymeworks Inc.